A MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, 2-ARM, PHASE III STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ANIFROLUMAB ADMINISTERED AS SUBCUTANEOUS INJECTION AND ADDED TO STANDARD OF CARE COMPARED WITH PLACEBO ADDED TO STANDARD OF CARE IN ADULT PARTICIPANTS WITH POLYMYOSITIS (JASMINE) (D3463C00003)